\
&
Contact us
This was 1 year ago
LocationBrussels
The European Commission, in close collaboration with the European Health and Digital Executive Agency (HaDEA), is organising the first Connecting Europe Facility - CEF Digital - community event.
The event will gather all the projects funded under the CEF Digital programme and players from all segments of the connectivity value chain in order to share experience, identify collaboration needs, strengthen synergies and contribute to maximising the programme’s impact on policy goals.
By engaging in discussions and exchanges of ideas, the CEF Digital community will bring new insights into the reflections on future connectivity policies and investments as outlined in the White Paper.
The morning will be dedicated to a presentation of the projects’ common objectives, with a focus on the identification of possible future synergies, while in the afternoon, the attention will shift to exploring financing options for connectivity infrastructures.
While CEF Digital is an EU funding programme independent of Horizon Europe or Digital Europe, it might contain interesting opportunities for stakeholders interested in Horizon Europe Cluster 4 or Digital Europe.
Please visit the event website to find our more about the agenda and to register.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.